11 unchanged sentences
On December 6, 2023, the Company’s Board of Directors approved an increase to its stock repurchase program authorization from $250 million to $500 million.
−Removed: This program has no specified expiration date.
+Added: This program was completed in December 2024.
The following table provides certain information with respect to the Company’s repurchases of common stock from October 1, 2024 through December 31, 2024:
4 unchanged sentences
3,938,408 $ 22.85 3,938,408 $ —
+Added: In January 2025, the Board of Directors approved a new stock repurchase program authorizing the repurchase of up to $500 million of our common stock.
Stock Performance Graph
−Removed: The following graph compares the total cumulative returns of BioScrip through August 6, 2019 and Option Care Health from August 7, 2019 through December 31, 2023 with the total cumulative returns of the Nasdaq Composite Index and the S&P Health Care Services Select Industry Index for the five-year period from December 31, 2018 through December 31, 2023.
+Added: The following graph compares the total cumulative returns of Option Care Health, the Nasdaq Composite Index and the S&P Health Care Services Select Industry Index for the five-year period from December 31, 2019 through December 31, 2024.
The graph shows the performance of a $100 investment in our Common Stock and each index as of December 31, 2019.
7 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.